AIM ImmunoTech Inc. is an immuno-pharma company developing therapeutics across cancer, immune disorders, and viral diseases. Its lead product, Ampligen (rintatolimod), is being developed for multiple indications including oncology and immune-related conditions.
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05927142 |
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy |
RECRUITING | PHASE1/PHASE2 |
| NCT05592418 |
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions |
COMPLETED | PHASE2 |
| NCT05494697 |
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC |
SUSPENDED | PHASE2 |
| NCT04379518 |
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients |
TERMINATED | PHASE1/PHASE2 |
| NCT03899987 |
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03734692 |
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03599453 |
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer |
COMPLETED | EARLY_PHASE1 |
| NCT02432378 |
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines |
TERMINATED | PHASE1/PHASE2 |
| NCT01591473 |
Safety Study of FluMist With and Without Ampligen |
TERMINATED | PHASE1/PHASE2 |
| NCT01545141 |
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer |
TERMINATED | PHASE1/PHASE2 |
